Husa Ml Petr, Husa Petr
Vnitr Lek. 2021 Winter;67(8):455-458.
Hepatitis C virus (HCV) infection is still a major cause of chronic liver diseases, with approximately 71 million chronically infected persons worldwide. People who inject drugs currently or in the past (PWID), mostly intravenously, are the main risk group among HCV chronically infected persons. The efficacy of therapy with direct-acting antivirals (DAA) is almost 100 %. Currently, the main mission is to diagnose HCV infection in the most possible number of infected persons; it is in collision with poor adherence of PWID in particular. Changing the spectrum of chronic hepatitis C patients forces medical professionals to change their approach to diagnosis and treatment of HCV infection. Outreach testing and cooperation with support organizations showed to be an effective way to set a course to eliminate HCV in the PWID population.
丙型肝炎病毒（HCV）感染仍是慢性肝病的主要病因，全球约有7100万慢性感染者。目前或过去注射毒品的人（主要通过静脉注射）是HCV慢性感染者中的主要风险群体。直接抗病毒药物（DAA）治疗的疗效几乎为100%。目前，主要任务是尽可能多地诊断出HCV感染者；这尤其与注射毒品者的依从性差相冲突。慢性丙型肝炎患者群体的变化迫使医学专业人员改变他们对HCV感染的诊断和治疗方法。扩大检测范围以及与支持组织合作被证明是在注射毒品者群体中朝着消除HCV方向努力的有效途径。
